BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gergianaki I, Bertsias G. Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. Front Med (Lausanne) 2018;5:161. [PMID: 29896474 DOI: 10.3389/fmed.2018.00161] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Karremah MF, Hassan RY, Faloudah AZ, Alharbi LK, Shodari AF, Rahbeeni AA, Alharazi NK, Binjabi AZ, Cheikh MM, Manasfi H, Abdulaziz S, Hussein AH, Alhazmi A, Almoallim H. From Symptoms to Diagnosis: An Observational Study of the Journey of SLE Patients in Saudi Arabia. Open Access Rheumatol 2022;14:103-11. [PMID: 35791408 DOI: 10.2147/OARRR.S362833] [Reference Citation Analysis]
2 Stappers S, van der Graaff D, Hoffman I, Moorkens W, Hantson I, Stappaerts I, Nowé V, Vervliet L. Systemic lupus erythematosus presenting as non-resolving pneumonia: a case report. Acta Clin Belg 2022;77:616-23. [PMID: 34027835 DOI: 10.1080/17843286.2021.1925817] [Reference Citation Analysis]
3 van Vollenhoven R, Askanase AD, Bomback AS, Bruce IN, Carroll A, Dall'Era M, Daniels M, Levy RA, Schwarting A, Quasny HA, Urowitz MB, Zhao MH, Furie R. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus Sci Med 2022;9:e000634. [PMID: 35346982 DOI: 10.1136/lupus-2021-000634] [Reference Citation Analysis]
4 Broadway-duren JB, Cesario SK. The Lived Experiences of Women Seeking a Diagnosis of Systemic Lupus Erythematosus. The Journal for Nurse Practitioners 2022. [DOI: 10.1016/j.nurpra.2022.01.019] [Reference Citation Analysis]
5 Papageorgiou L, Alkenaris H, Zervou MI, Vlachakis D, Matalliotakis I, Spandidos DA, Bertsias G, Goulielmos GN, Eliopoulos E. Epione application: An integrated web‑toolkit of clinical genomics and personalized medicine in systemic lupus erythematosus. Int J Mol Med 2022;49:8. [PMID: 34791504 DOI: 10.3892/ijmm.2021.5063] [Reference Citation Analysis]
6 Petrou P. A Systematic Review of the Economic Evaluations of Belimumab in Systemic Lupus Erythematosus. Value Health Reg Issues 2021;27:32-40. [PMID: 34784546 DOI: 10.1016/j.vhri.2021.06.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Tummala R, Abreu G, Pineda L, Michaels MA, Kalyani RN, Furie RA, Morand EF. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials. Lupus Sci Med 2021;8:e000464. [PMID: 33597205 DOI: 10.1136/lupus-2020-000464] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
8 Orme ME, Voreck A, Aksouh R, Ramsey-Goldman R, Schreurs MWJ. Systematic review of anti-dsDNA testing for systemic lupus erythematosus: A meta-analysis of the diagnostic test specificity of an anti-dsDNA fluorescence enzyme immunoassay. Autoimmun Rev 2021;20:102943. [PMID: 34508916 DOI: 10.1016/j.autrev.2021.102943] [Reference Citation Analysis]
9 Kapsala N, Nikolopoulos D, Flouda S, Chavatza A, Tseronis D, Aggelakos M, Katsimbri P, Bertsias G, Fanouriakis A, Boumpas DT. First diagnosis of systemic lupus erythematosus in hospitalized patients: Clinical phenotypes and pitfalls for the non-specialist. Am J Med 2021:S0002-9343(21)00500-3. [PMID: 34411524 DOI: 10.1016/j.amjmed.2021.07.015] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Hansen RB, Simard JF, Faurschou M, Jacobsen S. Distinct patterns of comorbidity prior to diagnosis of incident systemic lupus erythematosus in the Danish population. J Autoimmun 2021;123:102692. [PMID: 34364172 DOI: 10.1016/j.jaut.2021.102692] [Reference Citation Analysis]
11 Nimesh S, Ahmad MI, Dhama S, Kumar P, Akram M, Hasaroeih NEN. Systemic Lupus Erythematosus Disease: An Overview of the Clinical Approach to Pathogenesis, Diagnosis, and Treatment. Borneo J Pharm 2021;4:91-8. [DOI: 10.33084/bjop.v4i2.1950] [Reference Citation Analysis]
12 Chang A, Winquist NW, Wescott AB, Lattie EG, Graham AK. Systematic review of digital and non-digital non-pharmacological interventions that target quality of life and psychological outcomes in adults with systemic lupus erythematosus. Lupus 2021;30:1058-77. [PMID: 33779388 DOI: 10.1177/09612033211005085] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Adamichou C, Genitsaridi I, Nikolopoulos D, Nikoloudaki M, Repa A, Bortoluzzi A, Fanouriakis A, Sidiropoulos P, Boumpas DT, Bertsias GK. Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2021:annrheumdis-2020-219069. [PMID: 33568388 DOI: 10.1136/annrheumdis-2020-219069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
14 Piedra-Quintero ZL, Wilson Z, Nava P, Guerau-de-Arellano M. CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity. Front Immunol 2020;11:597959. [PMID: 33329591 DOI: 10.3389/fimmu.2020.597959] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
15 Hovde AM, McFarland CA, Garcia GM, Gallagher F, Gewanter H, Klein-Gitelman M, Moorthy LN. Multi-pronged approach to enhance education of children and adolescents with lupus, caregivers, and healthcare providers in New Jersey: Needs assessment, evaluation, and development of educational materials. Lupus 2021;30:86-95. [PMID: 33210558 DOI: 10.1177/0961203320969975] [Reference Citation Analysis]
16 Radmanesh F, Mahmoudi M, Yazdanpanah E, Keyvani V, Kia N, Nikpoor AR, Zafari P, Esmaeili SA. The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus. IUBMB Life 2020;72:2366-81. [PMID: 33006813 DOI: 10.1002/iub.2387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Fouda ME, Nour El Din DM, Mahgoub MY, Elashkar AE, Abdel Halim WA. Genetic variants of microRNA-146a gene: an indicator of systemic lupus erythematosus susceptibility, lupus nephritis, and disease activity. Mol Biol Rep 2020;47:7459-66. [PMID: 32929657 DOI: 10.1007/s11033-020-05802-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Firizal AS, Sugianli AK, Hamijoyo L. Cut off point of neutrophil-to-lymphocyte ratio as a marker of active disease in systemic lupus erythematosus. Lupus 2020;29:1566-70. [PMID: 32807022 DOI: 10.1177/0961203320950822] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Clausen J. [Participatory research in the German Rheumatism League. Content implementation and practical realisation of participatory research in a patient organisation]. Z Evid Fortbild Qual Gesundhwes 2020;155:64-70. [PMID: 32753283 DOI: 10.1016/j.zefq.2020.04.004] [Reference Citation Analysis]
20 Eldeiry D, Zandy M, Tayer-shifman OE, Kwan A, Marzouk S, Su J, Bingham K, Touma Z. Association between depression and anxiety with skin and musculoskeletal clinical phenotypes in systemic lupus erythematosus. Rheumatology 2020;59:3211-20. [DOI: 10.1093/rheumatology/keaa098] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
21 Torricelli AK, Ugolini-Lopes MR, Bonfá E, Andrade D. Antiphospholipid syndrome damage index (DIAPS): distinct long-term kinetic in primary antiphospholipid syndrome and antiphospholipid syndrome related to systemic lupus erythematosus. Lupus 2020;29:256-62. [PMID: 31986962 DOI: 10.1177/0961203320901598] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
22 James JA, Chen H, Young KA, Bemis EA, Seifert J, Bourn RL, Deane KD, Demoruelle MK, Feser M, O'Dell JR, Weisman MH, Keating RM, Gaffney PM, Kelly JA, Langefeld CD, Harley JB, Robinson W, Hafler DA, O'Connor KC, Buckner J, Guthridge JM, Norris JM, Holers VM. Latent autoimmunity across disease-specific boundaries in at-risk first-degree relatives of SLE and RA patients. EBioMedicine 2019;42:76-85. [PMID: 30952617 DOI: 10.1016/j.ebiom.2019.03.063] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
23 Adawi M, Bragazzi NL, McGonagle D, Watad S, Mahroum N, Damiani G, Conic R, Bridgewood C, Mahagna H, Giacomelli L, Eggenhöffner R, Mahamid M, Pigatto PDM, Amital H, Watad A. Immunogenicity, safety and tolerability of anti-pneumococcal vaccination in systemic lupus erythematosus patients: An evidence-informed and PRISMA compliant systematic review and meta-analysis. Autoimmun Rev 2019;18:73-92. [PMID: 30408581 DOI: 10.1016/j.autrev.2018.08.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]